Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Native T1 mapping in transthyretin amyloidosis.

Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, Pica S, Castelletti S, Piechnik SK, Robson MD, Gilbertson JA, Rowczenio D, Hutt DF, Lachmann HJ, Wechalekar AD, Whelan CJ, Gillmore JD, Hawkins PN, Moon JC.

JACC Cardiovasc Imaging. 2014 Feb;7(2):157-65. doi: 10.1016/j.jcmg.2013.10.008. Epub 2014 Jan 8.

2.

Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis.

Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan CJ, Myerson SG, Robson MD, Hawkins PN, Neubauer S, Moon JC.

JACC Cardiovasc Imaging. 2013 Apr;6(4):488-97. doi: 10.1016/j.jcmg.2012.11.013. Epub 2013 Mar 14.

3.

Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis.

Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, Lane T, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD.

Eur Heart J Cardiovasc Imaging. 2014 Nov;15(11):1289-98. doi: 10.1093/ehjci/jeu107. Epub 2014 Jun 16.

PMID:
24939945
4.

Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid.

Hutt DF, Fontana M, Burniston M, Quigley AM, Petrie A, Ross JC, Page J, Martinez-Naharro A, Wechalekar AD, Lachmann HJ, Quarta CC, Rezk T, Mahmood S, Sachchithanantham S, Youngstein T, Whelan CJ, Lane T, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD.

Eur Heart J Cardiovasc Imaging. 2017 Feb 4. doi: 10.1093/ehjci/jew325. [Epub ahead of print]

PMID:
28159995
5.

(99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis.

Pilebro B, Suhr OB, Näslund U, Westermark P, Lindqvist P, Sundström T.

Ups J Med Sci. 2016;121(1):17-24. doi: 10.3109/03009734.2015.1122687. Epub 2016 Feb 5.

6.

CMR-based differentiation of AL and ATTR cardiac amyloidosis.

Dungu JN, Valencia O, Pinney JH, Gibbs SD, Rowczenio D, Gilbertson JA, Lachmann HJ, Wechalekar A, Gillmore JD, Whelan CJ, Hawkins PN, Anderson LJ.

JACC Cardiovasc Imaging. 2014 Feb;7(2):133-42. doi: 10.1016/j.jcmg.2013.08.015. Epub 2014 Jan 8.

7.

Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis.

Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, Maestrini V, Barcella W, Rosmini S, Bulluck H, Sayed RH, Patel K, Mamhood S, Bucciarelli-Ducci C, Whelan CJ, Herrey AS, Lachmann HJ, Wechalekar AD, Manisty CH, Schelbert EB, Kellman P, Gillmore JD, Hawkins PN, Moon JC.

Circulation. 2015 Oct 20;132(16):1570-9. doi: 10.1161/CIRCULATIONAHA.115.016567. Epub 2015 Sep 11.

8.

Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study.

Fontana M, Banypersad SM, Treibel TA, Abdel-Gadir A, Maestrini V, Lane T, Gilbertson JA, Hutt DF, Lachmann HJ, Whelan CJ, Wechalekar AD, Herrey AS, Gillmore JD, Hawkins PN, Moon JC.

Radiology. 2015 Nov;277(2):388-97. doi: 10.1148/radiol.2015141744. Epub 2015 May 21.

PMID:
25997029
9.

Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR).

Pilebro B, Arvidsson S, Lindqvist P, Sundström T, Westermark P, Antoni G, Suhr O, Sörensen J.

J Nucl Cardiol. 2016 Sep 19. [Epub ahead of print]

PMID:
27645889
10.

Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis.

Connors LH, Prokaeva T, Lim A, Théberge R, Falk RH, Doros G, Berg A, Costello CE, O'Hara C, Seldin DC, Skinner M.

Am Heart J. 2009 Oct;158(4):607-14. doi: 10.1016/j.ahj.2009.08.006.

PMID:
19781421
11.

Cardiac amyloidosis: updates in diagnosis and management.

Mohty D, Damy T, Cosnay P, Echahidi N, Casset-Senon D, Virot P, Jaccard A.

Arch Cardiovasc Dis. 2013 Oct;106(10):528-40. doi: 10.1016/j.acvd.2013.06.051. Epub 2013 Sep 23. Review.

12.

The Utility of 99mTc-DPD Scintigraphy in the Diagnosis of Cardiac Amyloidosis: An Australian Experience.

Moore PT, Burrage MK, Mackenzie E, Law WP, Korczyk D, Mollee P.

Heart Lung Circ. 2017 Feb 16. pii: S1443-9506(17)30061-6. doi: 10.1016/j.hlc.2016.12.017. [Epub ahead of print]

PMID:
28256403
13.

Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study.

aus dem Siepen F, Buss SJ, Andre F, Seitz S, Giannitsis E, Steen H, Katus HA, Kristen AV.

Clin Res Cardiol. 2015 Aug;104(8):640-7. doi: 10.1007/s00392-015-0826-3. Epub 2015 Feb 18.

PMID:
25855392
14.

Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging.

Barison A, Aquaro GD, Pugliese NR, Cappelli F, Chiappino S, Vergaro G, Mirizzi G, Todiere G, Passino C, Masci PG, Perfetto F, Emdin M.

J Intern Med. 2015 May;277(5):605-14. doi: 10.1111/joim.12324. Epub 2014 Nov 24.

15.

Extracellular Volume Detects Amyloidotic Cardiomyopathy and Correlates With Neurological Impairment in Transthyretin-familial Amyloidosis.

Gallego-Delgado M, González-López E, Muñoz-Beamud F, Buades J, Galán L, Muñoz-Blanco JL, Sánchez-González J, Ibáñez B, Mirelis JG, García-Pavía P.

Rev Esp Cardiol (Engl Ed). 2016 Oct;69(10):923-930. doi: 10.1016/j.rec.2016.02.027. Epub 2016 Jun 10. English, Spanish.

PMID:
27291669
16.

(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses.

Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS.

Circ Cardiovasc Imaging. 2013 Mar 1;6(2):195-201. doi: 10.1161/CIRCIMAGING.112.000132. Epub 2013 Feb 11.

17.

Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis.

Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, Ferlini A, Longhi S, Lorenzini M, Reggiani LB, Gagliardi C, Gallo P, Villani C, Salvi F.

JACC Cardiovasc Imaging. 2011 Jun;4(6):659-70. doi: 10.1016/j.jcmg.2011.03.016.

18.

Noninvasive risk stratification of patients with transthyretin amyloidosis.

Kristen AV, Scherer K, Buss S, aus dem Siepen F, Haufe S, Bauer R, Hinderhofer K, Giannitsis E, Hardt S, Haberkorn U, Katus HA, Steen H.

JACC Cardiovasc Imaging. 2014 May;7(5):502-10. doi: 10.1016/j.jcmg.2014.03.002. Epub 2014 Apr 9.

19.

Cardiac transthyretin amyloidosis.

Dungu JN, Anderson LJ, Whelan CJ, Hawkins PN.

Heart. 2012 Nov;98(21):1546-54. doi: 10.1136/heartjnl-2012-301924. Epub 2012 Aug 11. Review.

PMID:
22888163
20.

Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.

Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN.

Circulation. 2016 Jun 14;133(24):2404-12. doi: 10.1161/CIRCULATIONAHA.116.021612. Epub 2016 Apr 22.

PMID:
27143678

Supplemental Content

Support Center